Thermo Fisher Scientific (TMO)

All the tools and services that the healthcare industry needs, so you get diversity with just the one stock. Very well managed. Long-term growth targets are 7-9%. Always improves margins. China is about 8% of revenues, a bit weaker. Biotech funding dried up with higher rates. Inventory destocking. Hopefully, those 3 factors are behind them.

Likes it. Great job improving ROE, pretty stable sales growth. Estimate for 2025 is 11-12% earnings growth. Technically, sets up well.

Benefitted from Covid, but afterwards there was too much inventory. But the PE fell from 30x to 20x, and is exiting the excess and entering a long cycle. Will grow earning 10-15% including by acquisition. Healthcare/pharma/biotech he expects will grow.

It made a buy list today and deserved it. They're starting to see a rebound after Covid. They have a lot of diagnostic equipment that's widely used across healthcare. Shares are earnings are coming out of the doldrums and starting to move up.

World leader, dominates the industry. Not cheap, but solid long-term grower.

Still very positive, especially as spending by pharmaceuticals is getting more robust.

They delivered today a strong earnings and revenue beat as they raised their full-year forecast. Thinks this the last quarter of revenue shrinkage before it gets a major rise in the second half of 2024.

Subdued returns. A leader, critical player in its sector. Stock's lagged due to inventory destocking, higher interest rates, and softer Chinese economy. These issues are largely resolved.

It is the leading company for testing new drugs. It has grown from acquisitions and is now growing at a rate of 5 to7% a year. Buy and hold.

Higher interest rates saw weaker funding in biotech. China had weak demand, though only about 8% of revenues. Still likes it long term for a picks and shovels play.

Avoid TMO because their revenues are flattening. Both trade at a high PE. BDX hasn't done much in share movement. He'd rather pay more for Boston Scientific which performs better.

Not a major growth company, but will grow steady. ~7% top line growth expected to continue. ~10% share price appreciation expected going forward. Will continue to hold in portfolio. 

It's retraced a big move, so it's buying opportunity.  Healthcare services technology is great place to be.

Last week, they reported strong earnings and an in-line full-year forecast, but stocks fell nearly 5%. That was a sell-the-news reaction, he thinks. Management said that 2023 was their transition year when they unwound excess inventory and 2024 is their recovery year, particularly in the second half. Buy it now. Macro trends: he thinks we're starting a huge innovation cycle in pharma in weight-loss drugs among others, all helped by generative AI. Biopharma is entering a red-hot period after years of pain.

He bought this in mid-2023 on a dip. It's been consolidating the healthcare space for the last 10 years. Are #1 in this space. He expects sales and their PE to improve.